medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2016, Number 3

<< Back Next >>

An Med Asoc Med Hosp ABC 2016; 61 (3)

Use of anticoagulant and antiplatelet therapy during endoscopic procedures

Estradas TJA, Angulo MD, Farca BA, Salceda OJC, Lozoya GD, Palomo HRA

Language: Spanish
References: 18
Page: 202-208
PDF size: 201.74 Kb.


ABSTRACT

Currently, new anticoagulant and antiplatelet agents are being indicated for the prophylaxis and treatment of several thrombotic diseases; their benefit has been well established. All antithrombotic agents increase the risk of hemorrhagic complications associated with invasive procedures. Risk stratification of endoscopic procedures is based on the risk of hemorrhage, and the one for discontinuation of an antithrombotic therapy is based on the risk of thrombosis of each clinical scenario. Every time a patient needs an endoscopy, it is imperative to analyze the hemorrhagic risk associated with the type of procedure vs. the thrombotic risk associated with the discontinuation of the antithrombotic agent. In this review article, we enlist the most recent recommendations about managing patients on antiplatelet or anticoagulant therapy who need to undergo an endoscopy.


REFERENCES

  1. Veitch AM, Vanbiervliet G, Gershlick AH, Boustiere C, Baglin TP, Smith LA et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopy. 2016; 48 (4): 385-402.

  2. Ono S, Fujishiro M, Kodashima S, Takahashi Y, Minatsuki C, Mikami-Matsuda R et al. Evaluation of safety of endoscopic biopsy without cessation of antithrombotic agents in Japan. J Gastroenterol. 2012; 47 (7): 770-774.

  3. Whitson MJ, Dikman AE, von Althann C, Sanyal S, Desai JC, Bamji ND et al. Is gastroduodenal biopsy safe in patients receiving aspirin and clopidogrel?: a prospective, randomized study involving 630 biopsies. J Clin Gastroenterol. 2011; 45 (3): 228-233.

  4. Rutter MD, Nickerson C, Rees CJ, Patnick J, Blanks RG. Risk factors for adverse events related to polypectomy in the English Bowel Cancer Screening Programme. Endoscopy. 2014; 46 (2): 90-97.

  5. Sawhney MS, Salfiti N, Nelson DB, Lederle FA, Bond JH. Risk factors for severe delayed postpolypectomy bleeding. Endoscopy. 2008; 40 (2): 115-119.

  6. Qumseya BJ, Wolfsen C, Wang Y, Othman M, Raimondo M, Bouras E et al. Factors associated with increased bleeding post-endoscopic mucosal resection. J Dig Dis. 2013; 14 (3): 140-146.

  7. Cui PJ, Yao J, Zhao YJ, Han HZ, Yang J. Biliary stenting with or without sphincterotomy for malignant biliary obstruction: a meta-analysis. World J Gastroenterol. 2014; 20 (38): 14033-14039.

  8. Bassan M, Bourke M. Endoscopic ampullectomy: a practical guide. J Interv Gastroenterol. 2012; 2 (1): 23-30.

  9. Al-Haddad M, Gill KR, Raimondo M, Woodward TA, Krishna M, Crook JE et al. Safety and efficacy of cytology brushings versus standard fine-needle aspiration in evaluating cystic pancreatic lesions: a controlled study. Endoscopy. 2010; 42 (2): 127-132.

  10. Vanbiervliet G, Giudicelli-Bornard S, Piche T, Berthier F, Gelsi E, Filippi J et al. Predictive factors of bleeding related to post-banding ulcer following endoscopic variceal ligation in cirrhotic patients: a case-control study. Aliment Pharmacol Ther. 2010; 32 (2): 225-232.

  11. Horiuchi A, Nakayama Y, Kajiyama M, Tanaka N, Sano K, Graham DY. Removal of small colorectal polyps in anticoagulated patients: a prospective randomized comparison of cold snare and conventional polypectomy. Gastrointest Endosc. 2014; 79 (3): 417-423.

  12. Gavin DR, Valori RM, Anderson JT, Donnelly MT, Williams JG, Swarbrick ET. The national colonoscopy audit: a nationwide assessment of the quality and safety of colonoscopy in the UK. Gut. 2013; 62 (2): 242-249.

  13. Yousfi M, Gostout CJ, Baron TH, Hernandez JL, Keate R, Fleischer DE et al. Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin. Am J Gastroenterol. 2004; 99 (9): 1785-1789.

  14. Korte W, Cattaneo M, Chassot PG, Eichinger S, von Heymann C, Hofmann N et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost. 2011; 105 (5): 743-749.

  15. Zeymer U, Hochadel M, Lauer B, Kaul N, Wöhrle J, Andresen D et al. Use, efficacy and safety of prasugrel in patients with ST segment elevation myocardial infarction scheduled for primary percutaneous coronary intervention in clinical practice. Results of the prospective ATACS-registry. Int J Cardiol. 2015; 184: 122-127.

  16. Baglin T. Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban. Br J Haematol. 2013; 163 (2): 160-167.

  17. Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost. 2015; 113 (3): 625-632.

  18. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012; 119 (13): 3016-3023.




2020     |     www.medigraphic.com